Reproductive endocrinologists should partner with obesity specialists to tailor joint clinics and shared care pathways that allow personalized dosing, side effect management, and monitoring of glycemic and reproductive biomarkers
Ninety-five percent of small papillary thyroid cancers tumors smaller than 1 centimeter don't grow or cause trouble for patients
Related links ACCG-2671: Amycretin: and and ASC30: Bioglutide: Bofanglutide: and CT-868: CT-996: and Danuglipron: and GSBR-1290: KAI-7535: KAI-9531: and and MET-097: and Orforglipron: and Pemvidutide: and Petrelintide: REDEFINE trials Cagri-Sema: and and Retatrutide: SURMOUNT-5 trial: The ESSENCE trial: The SOUL Trial: VK2735: Rights and permissions Springer Nature or its licensor (e.g
In patients treated with GLP-1RAs and tirzepatide, gastrointestinal side effects such as nausea and vomiting are common but do not significantly contribute to weight loss
If you are new to GLP-1 medications, invest time in educating yourself before starting
If glycaemic control deteriorates despite good adherence, your clinician may investigate alternative causes including antibody development
